Post-traumatic stress disorder by Seedat, Soraya
GUIDELINE
187    SAJP  -  August 2013  Vol. 19  No. 3 
1. Introduction
Post-traumatic stress disorder (PTSD) is among the most prevalent 
anxiety disorders, both in terms of lifetime and 12-month prevalence 
rates documented in epidemiological studies worldwide. The National 
Comorbidity Survey Replication (NCS-R) study conducted in the 
USA, for example, found the lifetime prevalence of PTSD to be 6.8% 
while the 12-month prevalence was 3.5%.[1,2] The South African 
Stress and Health Study (SASH) documented lower lifetime (2.3%) 
and 12-month (0.6%) rates, although PTSD was among the anxiety 
disorders with the highest proportion of severe cases (36% of all 
individuals diagnosed with PTSD were severely ill).[3] High rates of 
PTSD (19.9%) have also been documented among South African 
patients attending primary healthcare clinics.[4]
2. Diagnosis and clinical characteristics
The disorder represents a pathological response to a traumatic event, 
characterised by symptoms of recurrent and intrusive distressing 
recollections of the event (e.g. nightmares, a sense of reliving the 
experience with illusions, hallucinations, or dissociative flashback 
episodes, intense psychological or physiological distress at exposure 
to cues that resemble the traumatic event); avoidance of stimuli 
associated with the trauma (e.g. inability to recall important aspects of 
the trauma, loss of interest, estrangement from others); and increased 
arousal (sleep disturbances, irritability, difficulty concentrating, 
hypervigilance, and exaggerated startle response).[5] These symptoms 
cut across three recognised symptom clusters (re-experiencing, 
avoidance or numbing and hyperarousal), produce distress and 
impairment for individuals, and form the essential targets for 
treatment. The Diagnositic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-V) includes an additional cluster of symptoms 
characterised by negative alterations in cognition and mood. The 
full symptom picture must be present for more than 1 month for 
the diagnosis to be made.[6] PTSD is classified in the category of 
trauma- and stressor-related disorders, and separate from the anxiety 
disorders, in the DSM-V. Risk factors that increase the likelihood 
of PTSD include severity of the traumatic exposure, history of past 
trauma or previous psychiatric disorder, female gender, experience of 
further stressful events and lack of social support. 
3. Assessment
As a general rule, a comprehensive review of the differential diagnosis 
of the anxiety symptoms should be done, ruling out or treating other 
psychiatric diagnoses and medical causes. Thus, as part of the initial 
diagnostic assessment, and after each subsequent treatment trial, 
should response to treatment be unsatisfactory, it is important to 
evaluate symptoms associated with PTSD (e.g. insomnia, aggression, 
nightmares, suicidality, psychotic symptoms). Other considerations 
include comorbid diagnoses (including depression, other anxiety 
disorders, substance abuse, bipolar disorder), other issues such as 
concurrent medical illness especially that which may be undiagnosed 
(e.g. thyroid disease), ongoing trauma, and legal/compensation issues, 
ongoing use of anxiety-producing substances (e.g. caffeine, other 
stimulants), pregnancy, and poor adherence to treatment.[7] Those 
with PTSD, with and without depression, are at increased risk for 
suicidality, and it is important to assess suicide risk both at the initial 
evaluation and subsequent follow-up visits.[7] 
Longitudinal studies indicate that PTSD is a disorder of chronicity 
in that symptoms appear shortly after the traumatic event, subside 
in many individuals, but can persist in as many as 40% in the form 
of chronic PTSD.5 Given that a significant number of cases of PTSD 
are undiagnosed and undertreated, it is important to inquire about 
exposure to trauma, and to maintain a high index of suspicion and 
a high level of awareness of the disorder. Patients with PTSD are 
frequent users of general medical and psychiatric services, have 
high rates of coexisting psychiatric (e.g. major depressive disorder, 
alcohol and drug use disorders, other anxiety disorders) and medical 
conditions (e.g. asthma, gastrointestinal disorders), and, as already 
mentioned, are at a high risk for suicide attempts.[8,9] These comorbid 
diagnoses may complicate proper diagnosis and alter the course 
of treatment. The disorder is also highly reactive to environmental 
reminders of the traumatic event and to subsequent stressful life 
events and can therefore have a fluctuating course. 
4. Treatment
4.1 Treatment goals in PTSD
There are several specific goals of treatment that should all be borne in 
mind: reducing symptom severity; preventing the occurrence of, and/
or treating, comorbid disorders; decreasing functional impairment; 
modifying pathogenic fear schemas; building resilience; preventing 
relapse; and improving quality of life of patients.[10] The most common 
definitions of treatment response in PTSD patients are a decrease of 
30% or more[11] in the Clinician Administered PTSD Scale (CAPS) 
score[12] or a score of 1 (‘very much’) or 2 (‘much improved’)[13] in the 
Clinical Global Impressions Scale-Improvement item (CGI-I).[14]
4.2 General aspects of treatment
The treatment of PTSD has been the subject of several recent meta-
analyses and systematic reviews. Several treatment guidelines are 
available and these together have informed the treatment guideline 
that is recommended here. They include guidelines from the World 
Federation of Societies of Biological Psychiatry,[15] the US Institute 
of Medicine (IOM),[16] the American Psychiatric Association,[17] 
the UK National Institute of Clinical Excellence (NICE),[18] the 
Australian National Centre for PTSD,[19] the British Association for 
Psychopharmacology,[20] and the International Psychopharmacology 
Algorithm Project (IPAP).[7] All of these guidelines acknowledge that 
there are two distinct approaches that are of proven benefit in PTSD: 
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to be made is whether to offer medication, psychotherapy, or both. 
Psychotherapeutic treatments, if not used initially, can be added to, or 
replace pharmacotherapy. 
Chronic PTSD is defined as PTSD of more than 3 months’ duration. 
Most treatment guidelines recommend the use of either selective 
serotonin reuptake inhibitors (SSRIs) or exposure-based, trauma-
focused cognitive-behaviour therapy (TF-CBT) as first-line therapy. 
However, it should be mentioned that both the US IOM guidelines[16] 
and the UK NICE guidelines[18] on the sum of data suggest that 
evidence for the efficacy of pharmacological therapies, namely 
SSRIs, is at best tentative. The NICE guidelines,[18] for example, do 
not recommend drug treatments as a routine first line for adults 
with PTSD (for prescription either by a general practitioner or 
psychiatrist), but rather advocate for the use of TF-CBT.
4.3 Acute treatment 
An adequate trial requires 6 - 12 weeks, but the clinician should expect 
some response after 4 - 6 weeks with adequate dosage. A minimum 
course of exposure-based, TF-CBT is 8 - 12 weekly or biweekly 
sessions for exposure to a single-incident trauma. More sessions 
may be required in instances of multiple traumatic exposures or the 
presence of comorbidity.
4.4 Maintenance treatment
PTSD is a disorder that is characterised by symptom persistence and 
long-term treatment for at least 12 - 24 months is recommended. The 
SSRIs and the serotonin-norepinephrine reuptake inhibitor (SNRI), 
venlafaxine, have demonstrated long-term efficacy. 
4.5 Pharmacological treatment
The SSRIs and SNRIs are the two groups of antidepressants that 
have, to date, been the most rigorously studied in placebo-controlled 
randomised controlled trials (RCTs) and are considered as first-line 
agents for PTSD. Long-term efficacy (treatment for at least 12 - 24 
months) has also been demonstrated with both classes of agents.[15] 
Of the SSRIs, paroxetine, sertraline and fluoxetine currently have 
the best evidence for efficacy.[7,15-17] Paroxetine and sertraline are 
the only two that are US Food and Drug Administration (FDA) 
indicated for PTSD. In a meta-analysis of 35 RCTs (of 14 weeks or 
less in duration) involving a total of 4 597 participants, evidence 
for efficacy was most convincing for the SSRIs, across all symptom 
clusters and for co-occurring depression and disability.[13]  However, 
the SSRIs as a class seem to be less effective in combat-related PTSD 
than in non-combat-related PTSD.[17] Even when treated with this 
class of agents, response rates in PTSD rarely exceed 60% after a first 
trial of medication and less than 20 - 30% of patients achieve full 
remission. [7,15-17] This suggests that currently available, efficacious 
agents still fall short of the ideal because of limited response and 
remission rates, and tolerability issues.
4.6 Non-pharmacological treatment
There are now more than 50 published RCTs examining the efficacy 
of CBT for PTSD.[20] TF-CBT has the best established research base of 
well-designed RCTs. Prolonged exposure has been found to be highly 
effective in the treatment of women with PTSD following sexual or 
physical assault. A minimum course of 8 - 12 weekly or biweekly 
sessions is recommended. 
The components of CBT associated with the largest treatment effects 
are cognitive therapy (CT) and prolonged exposure; they have been 
shown to be superior to waitlist, supportive counselling, non-specific 
therapies; and treatment as usual.[21] Eye movement desensitisation and 
reprocessing (EMDR) which combines imaginal exposure with lateral 
eye movements, like exposure and CT, also has established efficacy, but 
critics of this procedure cite poor methodological quality and evidence 
that the procedural component, which is purported to differentiate 
it from exposure, is in fact ‘inactive’.[22] A recent Cochrane review[22] 
concluded that EMDR was more effective than traditional therapies 
or no therapy but not different from CBT and stress management.The 
IOM found the quality of the body of evidence for EMDR to be too low 
to inform conclusions regarding treatment efficacy.[16]
4.7 Special populations
4.7.1 Pregnancy and lactation
The risks of drug treatment during pregnancy need to be weighed 
against the risks of withholding treatment for PTSD. During the first 
trimester, SSRIs do not increase the risk of birth defects; the exception 
to this is paroxetine, which is associated with a 1.5-fold increased risk 
of congenital heart defects.[23] Clinical guidelines recommend that 
paroxetine be discontinued during pregnancy. SSRIs taken after 20 
weeks’ gestation may be associated with an increased risk of persistent 
pulmonary hypertension in the neonate, and all antidepressants 
administered in the third trimester may cause discontinuation 
effects (e.g. increased muscle tone, irritability, disrupted sleep, 
jitteriness) although these tend to be mild and self-limiting. Newer 
antidepressants, such as venlafaxine, have been associated with poor 
neonatal adaptation syndrome (tremors, irritability, shivering, feeding 
disturbances, increased muscle tone, respiratory difficulties) although 
it is unclear whether this is the result of medication withdrawal or 
toxicity. Treatment is supportive and symptoms usually resolve within 
2 weeks. Tricyclic antidepressants (TCAs) are regarded as relatively 
safe in pregnancy although there is an increased risk of preterm 
delivery compared with SSRIs or no antidepressants. Desipramine 
is the preferred TCA during pregnancy owing to its relatively 
weak anticholinergic effects.[24] Lithium (Ebstein’s anomaly) and 
antiepileptic medications such as carbamazepine (neural tube defects, 
craniofacial defects, cardiac malformations) and valproate (neural 
tube defects, spina bifida, pulmonary atresia) carry an increased 
risk of birth defects. To date, lamotrigine has not been associated 
with intrauterine growth defects or neurobehavioural toxicity. No 
significant risk of teratogenicity with the older atypical antipsychotics 
(olanzapine, risperidone, quetiapine) has been documented. However, 
the aforementioned antipsychotics are associated with maternal 
hyperglycaemia, impaired glucose tolerance and weight gain which 
could contribute to maternal complications during pregnancy.[24] 
Newer atypical antipsychotics (e.g. aripiprazole, ziprasidone) have 
been associated with delays in skeletal ossifications, increased fetal 
weight and fetal mortality.
Long-term safety data on the use of antidepressants in pregnancy 
are lacking. Important factors to consider include the time between 
medication administration and feeding, and infant size and infant 
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metabolism. Most SSRIs do not attain detectable levels in breast 
milk and are not associated with disturbed infant development or 
neuropathology. Sertraline and paroxetine may be good choices for 
lactating women as these SSRIs have specifically been associated with 
undetectable levels in infants. TCAs have been associated with few 
adverse effects in breastfed infants, while newer antidepressants such 
as venlafaxine and mirtazapine are considered to be moderately safe. 
4.7.2 Children and adolescents
Young children with PTSD, rather than reliving the trauma through 
repeated intrusive memories, may re-experience the trauma through 
repetitive play. Avoidance phenomena may also be more difficult 
to elicit in very young children who may struggle to verbalise their 
experiences. In addition to PTSD and acute stress disorder (ASD), 
traumatised children and adolescents may have a broad range of 
other psychopathological outcomes, in particular mood and anxiety 
disorders, behavioural disorders (e.g. attention-deficit hyperactivity 
disorder, conduct disorder), and substance use disorders. As with 
adults, interventions comprising psychotherapy (e.g. TF-CBT, family 
therapy) and pharmacotherapy (e.g. SSRIs, alpha-adrenergic agonists) 
are used. Practice parameters developed by the American Academy of 
Child and Adolescent Psychiatry[25] recommend that the treatment of 
mild PTSD begin with TF-CBT. Treatment studies suggest 12 sessions 
of TF-CBT where PTSD is uncomplicated, but a number of children 
and adolescents may require longer-term treatment. Currently little 
is known about the effectiveness of pharmacotherapeutic agents in 
paediatric PTSD as there have been few controlled studies of SSRIs. 
Children and adolescents with more severe PTSD and with comorbid 
mood and anxiety disorders are likely to benefit from an SSRI.[25]  
4.7.3 The elderly
The assessment and treatment of PTSD may pose challenges for 
psychiatrists involved in treating PTSD in older adults. Specific 
symptom profiles may differ in the older adult, particularly in those 
individuals with chronic PTSD. Distress when exposed to trauma-
related cues appears to be potentially salient and it is possible that 
this symptom motivates other features of PTSD in older adults, 
such as avoidance and emotional numbing.[26] This constellation of 
symptoms may lead to misdiagnosis, for example, major depression 
or dysthymic disorder. Several factors should be considered when 
selecting a medication for an older patient with PTSD. These include 
prior treatment response, target symptoms, concurrent physical 
illness and medications, and drug tolerability. In order to reach the 
optimal dose for an older patient without causing intolerable side-
effects, it is well worth remembering the adage ‘start low and go 
slow’. Important considerations in pharmacological treatment also 
include the heightened sensitivity for anticholinergic drug effects, 
increased sensitivity for extrapyramidal symptoms, an increased 
risk for orthostatic hypotension and electrocardiograph changes, 
and the possibility of paradoxical reactions (e.g. aggression) to 
benzodiazepines. SSRIs have been shown to be relatively safe in the 
elderly and are generally better tolerated than TCAs. Recommended 
doses of SSRIs for PTSD are the same as for younger adults. However, 
the potential for SSRIs to cause gastrointestinal and other bleeds, 
hyponatraemia, postural hypotension, and falls needs to be borne in 
mind in this age group.
4.8 Managing partial and non-responders
See steps 3 and 4 of algorithm below. 
4.9 Algorithm
Step 1. Initiating treatment
The starting dose can be low (fluoxetine 10 - 20 mg; sertraline 25  - 50 
mg; paroxetine, 10 - 20 mg; venlafaxine 37.5 - 75 mg). Other SSRIs 
include citalopram (10 - 20 mg), fluvoxamine (25 - 50 mg) and 
escitalopram (5 - 10 mg), for which there is less evidence. Based on 
currently available data for the SSRIs and SNRIs, statistically and 
clinically significant improvement is often seen by weeks 2 to 4. An 
adequate trial typically requires 6 - 12 weeks at an adequate dosage (e.g. 
fluoxetine 20 - 40 mg; sertraline 50 - 100 mg; paroxetine 20 - 40 mg), but 
some response should be expected after 4 - 6 weeks.[7] 
Other antidepressant options for which there is less robust 
evidence include mirtazapine, bupropion, and nefazodone. The 
older antidepressants, such as TCAs, e.g. amitriptyline, imipramine 
and the monoamine oxisase inhibitors (MAOIs, e.g. phenelzine) 
have demonstrated efficacy in placebo-controlled studies that have 
primarily included individuals with combat-related PTSD. In light 
of the safety profiles and concerns of toxicity with these agents 
(cardiotoxicity, seizure risk, and anticholinergic effects with the 
TCAs, and dietary restrictions and risk of hypertensive crisis with 
the MAOIs), they should preferably not be used as a first or second 
choice.[7,15-17] Table 1 lists recommended drug doses.[15] 
Step 2. Maintaining a response
It is important to note that while many patients will experience 
symptom improvement within 12 weeks with at least a 50% reduction 
in PTSD symptoms, further improvement in core symptoms, disability, 
and overall functioning often occurs with continued treatment. If a 
patient is adequately responsive (at least a 50% improvement) after 
12 weeks of treatment and demonstrates no intolerance, medication 
should be continued for at least 1 - 2 years . 
Step 3. Managing partial response
If the patient is only partially responsive to the first trial of medication 
(25 - 50% or more reduction in symptoms), it is prudent firstly to 
optimise the dose of medication (i.e. titrate up to the maximum 
allowed or tolerated dose). Before doing this, it is important to reassess 
for persisting core PTSD symptoms (intrusion, avoidance, numbing, 
and hyperarousal), sleep disturbances, other PTSD symptoms (e.g. 
irritability, hostility, aggression, panic, psychotic symptoms), bipolar 
spectrum disorder, and substance abuse.[7] 
These ongoing symptoms can be saliently targeted through 
augmentation strategies although it must be noted that the evidence-
base for augmentation strategies is limited. For example, olanzapine 
and risperidone (for which there is double-blind, placebo-controlled 
evidence for efficacy) can be used to target associated psychotic 
symptoms (e.g. paranoid ideation), and aggression. It is important 
to mention that since augmentation studies of antipsychotics 
were essentially short-term trials, the possibility of occurrence 
of severe adverse effects (viz. metabolic effects, cardiac effects, 
tardive dyskinesia) remain a concern. Anticonvulsants (e.g. valproate, 
lamotrigine, carbamazepine, topiramate), given their well-known 
anti-kindling properties, may also be effective as augmentation 
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for symptoms of irritability, impulsivity, labile mood, and anxiety, 
while alpha-1 inhibiting agents (e.g. prazosin, guanfacine) have 
shown promise in the treatment of nightmares, insomnia and other 
sleep-related disturbances in PTSD.[27] Hypotension, syncope and 
tachycardia are potential side-effects with prazosin; hence medical 
history, risks of hypotension and blood pressure monitoring should 
be considered. No data exist on the efficacy of benzodiazepines as 
augmentation treatment, although there are some data indicating 
their lack of efficacy as monotherapy (e.g. alprazolam) in chronic 
PTSD.[28] 
Exposure-based, TF-CBT (8 - 12 sessions) may also be considered 
as an augmentation strategy at this point. However, there are currently 
no published controlled studies of combined pharmacotherapy and 
psychotherapy in PTSD.
Step 4. Managing non-response
If there is no response (i.e. less than 25% improvement) to an SSRI 
and core PTSD symptoms persist after 4 - 6 weeks of an adequate 
medication dose (e.g. fluoxetine 40 mg/day, sertraline 150 mg/day), 
then it is advisable to switch to another SSRI, SNRI, or noradrenaline 
and specific serotonergic antidepressant (NaSSA) such as mirtazapine, 
bupropion; or alternatively to augment the same medication with 
another agent. The choice of an augmentation agent will depend on 
the presence of comorbid disorders; for example, the presence of a 
comorbid anxiety or mood disorder would probably necessitate the 
utilisation of an agent (e.g. antidepressant) that is effective for both 
PTSD and that disorder.[20] It is not known whether a sequential trial of 
a second SSRI is as effective as switching to an SNRI or NaSSA after the 
first unsuccessful SSRI trial. [20] If there is still no response after 6 - 12 
weeks, then it is recommended that one add an atypical antipsychotic, 
anticonvulsant, a TCA, or CBT. If the patient fails on all of the above, 
it is essential at this point to re-evaluate the diagnosis and to consider 
switching (e.g. to a TCA or MAOI if these have not been tried already) 
or to add a third medication. 
4.10 Early interventions for PTSD
TF-CBT is the only early intervention (i.e. given 1 - 3 months after 
trauma) that at the present time has convincing evidence of efficacy in 
ASD and acute PTSD.[20] There is no good evidence that psychological 
interventions (i.e. psychological debriefing), either single or multiple 
sessions, given routinely to everyone following a traumatic exposure, 
irrespective of symptoms, work. At present there is no conclusive 
evidence for the use of drug treatments to prevent PTSD in the early 
aftermath of trauma. Benzodiazepines are frequently prescribed in 
the aftermath of a traumatic event to control associated nonspecific 
behavioural disturbances (e.g. marked anxiety or agitation, insomnia) 
and/or to reduce active post-traumatic symptoms (e.g. hypervigilance). 
However, there is no compelling scientific evidence of the effectiveness 
of benzodiazepines either in the prevention of PTSD or in the treatment 
of core PTSD symptoms once they have developed.[22] In fact, there 
is evidence to indicate that benzodiazepines may contribute to the 
development and/or chronicity of PTSD symptoms.[28,29] 
5. Summary points
• PTSD is a challenging disorder to treat. 
• It should be recognised that the majority of individuals with PTSD 
in South Africa may not have guaranteed access to diagnostic, 
pharmacotherapeutic and evidence-based psychotherapeutic 
services as suggested in this guideline.
• Antidepressants (in particular SSRIs) and CBT (exposure-based, 
trauma-focused CBT) remain the mainstay of treatment for the 
disorder. 
• Use an SSRI or SNRI as first-line therapy and treat the patient at the 
maximum tolerated dose for at least 4 - 6 weeks before assessing 
responsiveness.
• Once a patient has responded to drug treatment, it should be 
continued for at least 12 - 24 months before considering gradual 
withdrawal.
• Cost should be factored into the choice of medication; the most 
affordable medication should preferably be selected to allow for 
funding of the minimum of 1 year of suggested pharmacotherapy.
• The minimum course of exposure-based, trauma-focused CBT is 
8 - 12 weekly or biweekly sessions for exposure to a single-incident 
trauma.
• In deciding on a treatment plan for the patient, it is important to 
consider the following at baseline and follow-up assessments: the 
presence of ongoing trauma, comorbid diagnoses (both psychiatric 
and medical), suicidality, substance abuse, psychosis, pregnancy, 
treatment compliance, pharmacokinetic (drug-drug interaction) 
issues, and legal or compensation issues.
• There is no evidence for the efficacy of systematic, brief, single-
session interventions (i.e. debriefing) focusing on the traumatic 
incident. However, providing general practical and social support and 
guidance to anyone following a traumatic incident is recommended.
Table 1. Recommended daily drug doses for post-traumatic 
stress disorder[15]*
Selective serotonin reuptake inhibitors (SSRIs)
Fluoxetine 20 - 40 mg
Sertraline 50 - 100 mg
Paroxetine 20 - 40 mg
Serotonin-norepinephrine reuptake inhibitors (SNRI)
Venlafaxine 75 - 300 mg
Noradrenergic and specific serotonergic antidepressants (NaSSA)
Mirtazapine 30 - 60 mg
Tricyclic antidepressants (TCAs)
Amitriptyline 75 - 200 mg
Imipramine 75 - 200 mg
Atypical antipsychotics
Risperidone 0.5 - 6 mg
Olanzapine (adjunctive) 2.5 - 20 mg
Other agents
Lamotrigine 25 - 500 mg
Prazosin (for nightmares) 1 - 10 mg
Phenelzine (MAOI) 45 - 90  mg
*Reprinted with permission from Bandelow B, Zohar J, Hollander E, et al. World Federation of 
Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxi-
ety, obsessive compulsive and post-traumatic stress disorders – first revision. World Journal of 
Biological Psychiatry 2008;9:248-312. Informa Healthcare. For educational purposes only.
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• The quest to investigate novel pharmacological agents (e.g. 
D-cycloserine, a partial agonist of N-methyl-D-aspartate (NMDA) 
receptor through its mechanism on fear extinction) and therapeutic 
strategies (e.g. virtual reality exposure therapy), for the management 
of PTSD remains an ongoing pursuit. 
• Several other novel agents (e.g. propranolol, hydrocortisone) have 
been investigated in the prevention of PTSD (i.e. as prophylaxis) 
with mixed results. Currently SSRIs are being investigated in 
placebo-controlled trials as an early intervention in ASD to prevent 
the later development of PTSD. However, there is insufficient 
evidence to recommend the use of any of these agents.
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